[A20-46] Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 17.08.2020
Project no.:
A20-46
Commission:
Commission awarded on 15.05.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Patients with high-risk non-metastatic castration-resistant prostate cancer
Disadvantages in some side effects do not question advantages particularly in overall survival; hint of considerable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-80 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-48 | Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A13-33 | Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A21-77 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |